Predicting Mortality in Patients with Tuberculous Destroyed Lung Receiving Mechanical Ventilation

Won-Young Kim, M.D.*©, Mi-Hyun Kim, M.D., Ph.D.*©, Eun-Jung Jo, M.D., Ph.D., Jung Seop Eom, M.D., Ph.D., Jeongha Mok, M.D., Ph.D., Ki Uk Kim, M.D., Ph.D., Hye-Kyung Park, M.D., Ph.D., Min Ki Lee, M.D., Ph.D. and Kwangha Lee, M.D., Ph.D.©
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea

Background: Patients with acute respiratory failure secondary to tuberculous destroyed lung (TDL) have a poor prognosis. The aim of the present retrospective study was to develop a mortality prediction model for TDL patients who require mechanical ventilation.

Methods: Data from consecutive TDL patients who had received mechanical ventilation at a single university-affiliated tertiary care hospital in Korea were reviewed. Binary logistic regression was used to identify factors predicting intensive care unit (ICU) mortality. A TDL on mechanical Ventilation (TDL-Vent) score was calculated by assigning points to variables according to β coefficient values.

Results: Data from 125 patients were reviewed. A total of 36 patients (29%) died during ICU admission. On the basis of multivariate analysis, the following factors were included in the TDL-Vent score: age ≥65 years, vasopressor use, and arterial partial pressure of oxygen/fraction of inspired oxygen ratio <180. In a second regression model, a modified score was then calculated by adding brain natriuretic peptide. For TDL-Vent scores 0 to 3, the 60-day mortality rates were 11%, 27%, 30%, and 77%, respectively (p<0.001). For modified TDL-Vent scores 0 to ≥3, the 60-day mortality rates were 0%, 21%, 33%, and 57%, respectively (p=0.001). For both the TDL-Vent score and the modified TDL-Vent score, the areas under the receiver operating characteristic curve were larger than that of other illness severity scores.

Conclusion: The TDL-Vent model identifies TDL patients on mechanical ventilation with a high risk of mortality. Prospective validation studies in larger cohorts are now warranted.

Keywords: Mechanical Ventilation; Mortality; Prognosis; Risk; Tuberculosis

Introduction

Tuberculous destroyed lung (TDL) results from inadequate treatment of pulmonary tuberculosis and progressive destruction of one or both lungs. In Korea, TDL is a common cause of pulmonary disability and respiratory failure, and the reported mortality rate is as high as 61%. A previous study by Ryu et al. revealed that TDL was an independent predictor of mortality in patients with acute respiratory failure requiring mechanical ventilation.

Several studies aimed to identify factors predicting mortality in TDL patients. Park et al. evaluated a cohort of 38 TDL patients requiring mechanical ventilation due to acute respiratory failure. The authors found that a positive acid-fast bacilli...
replacement therapy, and active infections) was also assessed.

Within 24 hours of ICU admission (i.e., vasopressor use, renal failure, organ dysfunction) was assessed using the Sequential Organ Failure Assessment (SOFA) score and the Acute Physiology and Chronic Health Evaluation (APACHE) II score. Severity was assessed using the two widely used illness severity scores.

The aims of the present retrospective study were to (1) develop a mortality prediction model termed the TDL on mechanical Ventilation (TDL-Vent) score using clinical variables obtained at the time of ICU admission; and (2) compare the ability of the TDL-Vent score to predict mortality with that of two widely used illness severity scores.

Materials and Methods

1. Study design and cohort

The study was conducted at the Pusan National University Hospital, which is a 1,100-bed university-affiliated hospital in Busan, Korea. Data from consecutive TDL patients who had been admitted to the medical ICU for mechanical ventilation between January 2005 and December 2016 were analyzed. Patients with destroyed lung secondary to other causes were excluded. The primary study outcome was ICU mortality. Secondary outcomes were duration of mechanical ventilation, tracheostomy during ICU stay, length of ICU and total hospital stay, and in-hospital, 28-day, and 60-day mortality. The study protocol was approved by the Institutional Review Board of Pusan National University Hospital (C-1708-028-058). The requirement for informed consent was waived, since the study was retrospective and all patient records were anonymized and de-identified prior to analysis.

2. Data collection and definitions

Baseline demographic and clinical characteristics included age, sex, body mass index, smoking status, comorbidities, and the major diagnosis leading to mechanical ventilation. Disease severity was assessed using the Acute Physiology and Chronic Health Evaluation (APACHE) II score and the Sequential Organ Failure Assessment (SOFA) score. Clinical status within 24 hours of ICU admission (i.e., vasopressor use, renal replacement therapy, and active infections) was also assessed.

Laboratory data included complete blood cell count, blood chemistry, and arterial blood gas analysis. Baseline chest X-ray and/or computed tomography scans from the day of ICU admission were reviewed to evaluate the degree of parenchymal lung destruction. To identify potential risk factors for mortality, results from pulmonary function tests conducted within the preceding 12 months, and echocardiography findings and brain natriuretic peptide (BNP) values from the day of ICU admission, were evaluated.

TDL was diagnosed on the basis of a history of present or past pulmonary tuberculosis and radiological evidence of parenchymal lung destruction, lung volume loss, or secondary bronchiectatic changes. Active infection was defined as the presence in a blood culture or adequate sputum culture, endotracheal aspirate, or bronchoscopy sample of a pneumonia pathogen (bacteria, including tuberculosis; a virus; or a fungus). To evaluate the extent of disease involvement, baseline chest X-rays were graded on a 4-point scale (field score 1–4) using a radiographic scoring method described elsewhere. First, four zones were demarcated by dividing each lung into two equal-sized zones (upper and lower) on a frontal radiograph. In each of the four zones, the following scoring system was then applied: (1) 0, no abnormality; (2) 1, when less than 25% of lung parenchyma showed destructive lung lesions; and (3) 2, 3, or 4, respectively, when destroyed lung lesions involved 25%–50%, 50%–75%, or >75% of lung parenchyma. The field score was then calculated as the mean disease involvement of the two lungs. Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV₁) were expressed as a percentage of the predicted normal values. The FVC and FEV₁ values were calculated using Korean equations, which were based on data from a non-smoking population with normal chest radiograph findings and no history of lung disease or symptoms. In these equations, the predicted value is adjusted in accordance with age, sex, height, and weight. Cor pulmonale was diagnosed on the basis of both clinical and echocardiographic findings. Echocardiographic signs of cor pulmonale comprised right ventricular (RV) hypertrophy or dilation accompanying high RV systolic pressure (> 35 mm Hg).

3. Statistical analysis

Continuous variables are presented as the median and interquartile range. Categorical variables are presented as percentages. Continuous variables were compared using a Mann–Whitney U test. Categorical variables were compared using a chi-square or Fisher exact test. The optimal cut-off values for potential predictors of ICU mortality were selected using either the median value or locally weighted scatterplot smoothing curves, as appropriate. Binary logistic regression analysis was performed to identify factors predicting ICU mortality. Variables with p-values of <0.20 in the univariate analysis were included in the multivariate analysis. Model
### Table 1. Baseline characteristics of the study cohort

| Variable                      | Total (n=125) | Survivors (n=89) | Nonsurvivors (n=36) | p-value |
|-------------------------------|---------------|------------------|---------------------|---------|
| Age, yr                       | 66 (57–74)    | 64 (56–72)       | 72 (62–76)          | 0.03    |
| Male sex                      | 104 (83)      | 72 (81)          | 32 (89)             | 0.28    |
| Body mass index, kg/m²        | 19.5 (16.7–22.2) | 19.9 (17.1–22.3) | 18.8 (15.1–22.2)   | 0.18    |
| Smoking                       |               |                  |                     | 0.43    |
| Never smoker                  | 66 (53)       | 49 (55)          | 17 (47)             |         |
| Ever smoker                   | 59 (47)       | 40 (45)          | 19 (53)             |         |
| Comorbidity                   |               |                  |                     |         |
| Diabetes                      | 25 (20)       | 17 (19)          | 8 (22)              | 0.69    |
| Hypertension                  | 31 (25)       | 25 (28)          | 6 (17)              | 0.18    |
| Heart disease                 | 30 (24)       | 21 (24)          | 9 (25)              | 0.87    |
| Cerebrovascular disease       | 10 (8)        | 5 (6)            | 5 (14)              | 0.15    |
| Chronic lung disease          | 53 (42)       | 38 (43)          | 15 (42)             | 0.92    |
| Chronic liver disease         | 8 (6)         | 7 (8)            | 1 (3)               | 0.44    |
| Chronic kidney disease        | 5 (4)         | 4 (5)            | 1 (3)               | >0.99   |
| Malignancy                    | 13 (10)       | 10 (11)          | 3 (8)               | 0.76    |
| Major diagnoses leading to MV |               |                  |                     |         |
| Pneumonia                     | 73 (58)       | 48 (54)          | 25 (69)             | 0.11    |
| Acute exacerbation            | 20 (16)       | 16 (18)          | 4 (11)              | 0.34    |
| Hemoptysis                    | 19 (15)       | 12 (14)          | 7 (19)              | 0.40    |
| Severity of illness           |               |                  |                     |         |
| APACHE II score               | 19 (15–24)    | 18 (15–23)       | 21 (18–28)          | 0.02    |
| SOFA score                    | 8 (4–11)      | 7 (4–10)         | 9 (7–11)            | 0.03    |
| Vasopressor use               | 58 (46)       | 33 (37)          | 25 (69)             | 0.001   |
| Renal replacement therapy     | 10 (8)        | 7 (8)            | 3 (8)               | >0.99   |
| Active infection              | 44 (35)       | 31 (35)          | 13 (36)             | 0.89    |
| Laboratory data               |               |                  |                     |         |
| PaO₂/FIO₂                     | 176 (120–241) | 197 (138–303)    | 139 (103–182)       | <0.001  |
| PaCO₂, mm Hg                  | 52 (42–65)    | 54 (42–64)       | 51 (39–70)          | 0.71    |
| Platelet count, 1,000 cells/mm³ | 224 (170–289) | 224 (170–278)    | 228 (161–300)       | 0.66    |
| Total bilirubin, mg/dL        | 0.7 (0.5–1.1) | 0.7 (0.5–1.0)    | 0.6 (0.5–1.1)       | 0.55    |
| Creatinine, mg/dL             | 0.8 (0.6–1.0) | 0.7 (0.6–1.0)    | 0.8 (0.6–1.1)       | 0.55    |
| Albumin, g/dL                 | 3.0 (2.6–3.7) | 3.1 (2.7–3.8)    | 2.9 (2.5–3.6)       | 0.28    |
| BNP pg/mL* (n=70/26)          | 333 (101–797) | 312 (89–669)     | 479 (210–908)       | 0.15    |
| Field score                   | 2 (2–2)       | 2 (2–2)          | 2 (2–2)             | 0.87    |
| Spirometric values† (n=40/14) |               |                  |                     |         |
| FVC, % of predicted           | 48 (35–59)    | 46 (35–58)       | 54 (36–67)          | 0.22    |
| FEV₁, % of predicted          | 40 (29–59)    | 37 (28–55)       | 46 (37–70)          | 0.21    |
| FEV₁/FVC                      | 0.63 (0.53–0.82) | 0.63 (0.54–0.80) | 0.65 (0.53–0.88)   | 0.84    |
| Echocardiography‡ (n=47/17)   |               |                  |                     |         |
| Ejection fraction, %          | 60 (56–60)    | 60 (56–63)       | 60 (53–60)          | 0.16    |
| High RVSP§, || (n=45/14)      | 35 (59)       | 26 (58)          | 9 (64)              | 0.67    |
| Cor pulmonale¶ (n=46/15)      | 26 (43)       | 20 (44)          | 6 (40)              | 0.81    |

Values are presented as the median (interquartile range) or number (%).

*No. of survivors/nonsurvivors=70/26. † No. of survivors/nonsurvivors=40/14. ‡ No. of survivors/nonsurvivors=47/17. § RVSP >35 mm Hg. ¶ No. of survivors/nonsurvivors=45/14. MV: mechanical ventilation; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; PaO₂: arterial partial pressure of oxygen; FIO₂: fraction of inspired oxygen; PaCO₂: arterial partial pressure of carbon dioxide; BNP: brain natriuretic peptide; FVC: forced vital capacity; FEV₁: forced expiratory volume in 1 second; RVSP: right ventricular systolic pressure.
discrimination was assessed using the area under the receiver operating characteristic curve (AUC), and model calibration was assessed using the Hosmer-Lemeshow test. The β coefficient values derived from multiple logistic regression were simplified to natural numbers >0, and the TDL-Vent score was calculated as the sum of these simplified values. To predict 60-day survival, Kaplan-Meier estimates were stratified according to the TDL-Vent score, and curves were compared using the log-rank test. The AUC for the TDL-Vent score predicting ICU mortality was compared with that for the APACHE II score and the SOFA score. Identification of an optimal cut-off value for the score was based on the maximum Youden’s index. All tests of significance were two-tailed, and p-values of <0.05 were considered significant. All analyses were performed using SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA) and MedCalc Statistical Software version 16.8.4 (MedCalc Software bvba, Ostend, Belgium).

Results

During the study period, 125 patients fulfilled the study inclusion criteria. Of these, 89 (71%) survived ICU admission. The remaining 36 (29%) patients died on the ICU.

Baseline characteristics of the study cohort are shown in Table 1. Nonsurvivors were older. No significant difference was found between survivors and nonsurvivors in terms of sex, body mass index, smoking status, or comorbidities. Mechanical ventilation was primarily due to pneumonia in 54% (48/89) of survivors and 69% (25/36) of non-survivors (p=0.11). Nonsurvivors had significantly higher APACHE II and SOFA scores and had a higher rate of vasopressor use within 24 hours of ICU admission. Active infection was found in 44 (35%) of the cohort, with no significant difference being found between survivors and non-survivors. The following pathogens were considered to be associated with pneumonia: methicillin-resistant Staphylococcus aureus (n=14), Acinetobacter (n=9), Mycobacterium tuberculosis (n=6), Pseudomonas (n=5), extended-spectrum beta-lactamase-producing organism (n=4), Klebsiella pneumoniae (n=3), Stenotrophomonas (n=3), and Aspergillus species (n=3). The median arterial partial pressure of oxygen (PaO_2) to fraction of inspired oxygen (FiO_2) ratio was significantly lower in non-survivors. Compared with survivors, non-survivors had numerically lower serum albumin and higher BNP. No significant differences were found between survivors and non-survivors with regard to other factors like FEV1/FVC ratio, age, body mass index, smoking status, or comorbidities. Mechanical ventilation was primarily due to pneumonia in 54% (48/89) of survivors and 69% (25/36) of non-survivors (p=0.11). Nonsurvivors had significantly higher APACHE II and SOFA scores and had a higher rate of vasopressor use within 24 hours of ICU admission. Active infection was found in 44 (35%) of the cohort, with no significant difference being found between survivors and non-survivors. The following pathogens were considered to be associated with pneumonia: methicillin-resistant Staphylococcus aureus (n=14), Acinetobacter (n=9), Mycobacterium tuberculosis (n=6), Pseudomonas (n=5), extended-spectrum beta-lactamase-producing organism (n=4), Klebsiella pneumoniae (n=3), Stenotrophomonas (n=3), and Aspergillus species (n=3). The median arterial partial pressure of oxygen (PaO_2)/fraction of inspired oxygen (FiO_2) ratio was significantly lower in non-survivors. Compared with survivors, non-survivors had numerically lower serum albumin and higher BNP. However, the survivor and non-survivor groups showed no significant differences in terms of left ventricular systolic function or the proportion of patients with high RV systolic pressure. Clinical outcomes in the cohort are shown in Table 2.

Table 2 shows the results of the univariate and multivariate analyses of risk factors predicting ICU mortality. The following cut-off values were identified via inspection of locally weighted scatterplot smoothing curves: age ≥65 years, PaO_2/FiO_2 ratio <180, PaCO_2 <52 mm Hg, serum albumin <3.0 g/dL, BNP ≥330 pg/mL, and field score ≥2 (Supplementary Figure S1). Based on the β coefficient values observed in model 1, a TDL-Vent score comprising the following factors was proposed: (1) age ≥65 years (+1 point); (2) vasopressor use (+1 point); and (3) PaO_2/FiO_2 ratio <180 (+1 point). This model had acceptable discrimination (AUC, 0.74) and calibration (Hosmer and Lemeshow chi-square, 14.74; p=0.06). Figure 1A shows the Kaplan-Meier survival curves, as stratified according to the TDL-Vent score. The 60-day mortality rates for scores ranging from 0 to 3 were 11%, 27%, 30%, and 77%, respectively (log-rank test, p<0.001). The AUC of the TDL-Vent score for predicting ICU mortality was 0.72 (95% confidence interval [CI], 0.63–0.80). This was larger than the AUC for the APACHE II score (0.63; 95% CI, 0.54–0.72) and SOFA score (0.62; 95% CI, 0.53–0.71) (Figure 2). The cut-off score for predicting mortality based on the maximum Youden’s index was ≥2, with a sensitivity of 44% and a specificity of 93%.

In model 2, BNP was included as an additional variable in the regression model, since pulmonary hypertension is associated with poor prognosis in chronic pulmonary tuberculosis and BNP is a non-invasive marker of pulmonary hypertension. In this model, the following modified TDL-Vent score was developed: (1) vasopressor use (+1 point); (2) PaO_2/FiO_2 ratio <180 (+2 points); and (3) BNP ≥330 pg/mL (+1 point). The model had acceptable discrimination (AUC, 0.76) and calibration (Hosmer and Lemeshow chi-square, 54.66; p=0.69). For modi-
Prognosis for TDL on mechanical ventilation

Table 3. Factors included in the TDL-Vent score

| Variable                        | Unadjusted OR (95% CI)  | p-value | Adjusted OR (95% CI)  | p-value | β value |
|---------------------------------|-------------------------|---------|-----------------------|---------|---------|
| Model 1*                        |                         |         |                       |         |         |
| Age ≥65 yr                      | 1.81 (0.82–4.02)        | 0.15    | 1.63 (0.68–3.95)      | 0.28    | 0.49    |
| Pneumonia                       | 1.94 (0.85–4.42)        | 0.11    | -                     | -       | -       |
| Vasopressor use                 | 3.86 (1.68–8.84)        | 0.001   | 3.47 (1.41–8.54)      | 0.007   | 1.24    |
| PaO₂/FiO₂ <180                  | 4.03 (1.70–9.55)        | 0.002   | 3.41 (1.34–8.65)      | 0.01    | 1.23    |
| PaCO₂ <52 mm Hg                 | 1.31 (0.60–2.84)        | 0.50    | -                     | -       | -       |
| Albumin <3.0 g/dL               | 1.88 (0.86–4.12)        | 0.12    | -                     | -       | -       |
| Field score ≥2                  | 1.01 (0.40–2.57)        | 0.98    | -                     | -       | -       |
| Model 2†                        |                         |         |                       |         |         |
| Age ≥65 yr                      | 1.81 (0.82–4.02)        | 0.15    | -                     | -       | -       |
| Pneumonia                       | 1.94 (0.85–4.42)        | 0.11    | -                     | -       | -       |
| Vasopressor use                 | 3.86 (1.68–8.84)        | 0.001   | 3.13 (1.10–8.88)      | 0.03    | 1.14    |
| PaO₂/FiO₂ <180                  | 4.03 (1.70–9.55)        | 0.002   | 4.61 (1.51–14.10)     | 0.007   | 1.53    |
| PaCO₂ <52 mm Hg                 | 1.31 (0.60–2.84)        | 0.50    | -                     | -       | -       |
| Albumin <3.0 g/dL               | 1.88 (0.86–4.12)        | 0.12    | -                     | -       | -       |
| BNP ≥330 pg/mL                  | 1.69 (0.68–4.25)        | 0.26    | 1.96 (0.70–5.45)      | 0.20    | 0.67    |
| Field score ≥2                  | 1.01 (0.40–2.57)        | 0.98    | -                     | -       | -       |

*Variables with p-values of <0.20 in the univariate analysis were included in the multivariate analysis. †BNP and the other variables with p-values of <0.20 in the univariate analysis were included in the multivariate analysis.

TDL-Vent: tuberculous destroyed lung on mechanical ventilation; OR: odds ratio; CI: confidence interval; PaO₂: arterial partial pressure of oxygen; FiO₂: fraction of inspired oxygen; PaCO₂: arterial partial pressure of carbon dioxide; BNP: brain natriuretic peptide.

Figure 1. Kaplan-Meier survival curves, as stratified according to the TDL-Vent score (A) and the modified TDL-Vent score (B). TDL-Vent: tuberculous destroyed lung on mechanical ventilation; ICU: intensive care unit.

Fied TDL-Vent scores ranging from 0 to ≥3, 60-day mortality rates were 0%, 21%, 33%, and 57%, respectively (log-rank test, p=0.001) (Figure 1B). The AUC of the modified TDL-Vent score for predicting ICU mortality was 0.74 (95% CI 0.64–0.82) (Figure 3). The cut-off score for predicting mortality was ≥2, with a sensitivity of 65% and a specificity of 71%. Table 4 shows the clinical outcomes of study patients, as stratified according to the TDL-Vent scores from models 1 and 2.
The present analyses indicated that age, vasopressor use, $\text{PaO}_2/\text{FiO}_2$ ratio, and BNP were reliable predictors of ICU mortality in TDL patients on mechanical ventilation. These factors were therefore included in the TDL-Vent score. This simple scoring system was more effective than either the APACHE II or the SOFA score in terms of predicting ICU mortality. To our knowledge, the present study is the first to evaluate a mortality risk scoring model for TDL patients on mechanical ventilation.

Several previous investigations of patients with active pulmonary tuberculosis and acute respiratory failure reported high rates of in-hospital mortality. Risk factors associated with mortality vary between studies. However, the most frequently reported risk factors are the requirement for mechanical ventilation, sepsis, organ failure, nosocomial pneumonia, and delayed treatment\textsuperscript{3,20,21}. TDL patients presenting with acute respiratory failure have a poor prognosis. However, few studies have investigated prognostic factors in such patients.

| Variable                  | TDL-Vent score | p-value |
|---------------------------|----------------|---------|
| MV-free days at day 60    | Score 0 (n=19) | Score 1 (n=44) | Score 2 (n=40) | Score 3 (n=22) | p-value |
|                           | 52 (35–56)     | 40 (0–53)   | 19 (0–53)   | 0 (0–0)     | <0.001  |
| ICU mortality             | 1 (5)          | 11 (25)     | 8 (20)      | 16 (73)     | <0.001  |
| In-hospital mortality     | 2 (11)         | 12 (27)     | 14 (35)     | 18 (82)     | <0.001  |
| 60-Day mortality          | 2 (11)         | 12 (27)     | 12 (30)     | 17 (77)     | <0.001  |

| Variable                  | TDL-Vent score | p-value |
|---------------------------|----------------|---------|
| MV-free days at day 60    | Score 0 (n=13) | Score 1 (n=19) | Score 2 (n=27) | Score 3–4 (n=37) | p-value |
|                           | 56 (52–57)     | 47 (0–53)   | 0 (0–48)     | 0 (0–48)     | 0.001   |
| ICU mortality             | 0              | 2 (11)      | 7 (26)       | 17 (46)      | 0.003   |
| In-hospital mortality     | 0              | 4 (21)      | 9 (33)       | 22 (60)      | <0.001  |
| 60-Day mortality          | 0              | 4 (21)      | 9 (33)       | 21 (57)      | 0.001   |

Values are presented as the median (interquartile range) or number (%).

*TDL-Vent: tuberculous destroyed lung on mechanical ventilation; MV: mechanical ventilation; ICU: intensive care unit; BNP: brain natriuretic peptide.*

Discussion

The present analyses indicated that age, vasopressor use, $\text{PaO}_2/\text{FiO}_2$ ratio, and BNP were reliable predictors of ICU mortality in TDL patients on mechanical ventilation. These factors were therefore included in the TDL-Vent score. This simple scoring system was more effective than either the APACHE II or the SOFA score in terms of predicting ICU mortality. To our knowledge, the present study is the first to evaluate a mortality risk scoring model for TDL patients on mechanical ventilation.

Several previous investigations of patients with active pulmonary tuberculosis and acute respiratory failure reported high rates of in-hospital mortality. Risk factors associated with mortality vary between studies. However, the most frequently reported risk factors are the requirement for mechanical ventilation, sepsis, organ failure, nosocomial pneumonia, and delayed treatment\textsuperscript{3,20,21}. TDL patients presenting with acute respiratory failure have a poor prognosis. However, few studies have investigated prognostic factors in such patients.
Previous studies show that AFB-positive TDL patients have more severe lung destruction and higher mortality rates than AFB-negative patients\textsuperscript{2,22}, while a higher level of PaCO\textsubscript{2} has been associated with increased survival\textsuperscript{2}. Ryu et al.\textsuperscript{7} found that a high field score was the only predictor of reduced survival, although patients with high field scores showed higher PaCO\textsubscript{2}. The aforementioned studies investigated small cohorts of mechanically ventilated patients, and their results were inconsistent. The main strength of the present study was its relatively large cohort, which was restricted to patients requiring mechanical ventilation. This enabled the development of an individualized mortality prediction score for this specific population. An interesting and unexpected finding of the present study was the lack of association between the degree of lung destruction, tuberculosis activity, or the level of PaCO\textsubscript{2} and increased mortality. Instead, the prognostic factors in the present cohort were age and evidence of organ failure (vasopressor use and PaO\textsubscript{2}/FiO\textsubscript{2} <180), as suggested in other patient populations. These risk factors are consistent with those reported in previous studies of active pulmonary tuberculosis with acute respiratory failure\textsuperscript{3,20,21}, thus supporting the hypothesis that lower physiologic reserve and organ dysfunction, rather than the destroyed lung per se, are better predictors of mortality in mechanically ventilated TDL patients. A low serum albumin level also correlated with mortality in active pulmonary tuberculosis with acute respiratory failure\textsuperscript{23}. In this study, non-survivors had lower levels of serum albumin than survivors, although this trend did not reach statistical significance. In the present cohort, the TDL-Vent score (both model 1 and model 2) was superior in terms of discriminating between survivors and non-survivors than either the APACHE II score or the SOFA score. In addition, the score from model 1 showed very high specificity in patients with the highest risk of mortality, thus limiting the possibility of misclassifying a patient as very high risk. This is crucial, as such a classification may result in the decision to withhold or withdraw life support. Lastly, the clinician is able to calculate the TDL-Vent score at the bedside, rather than relying on complicated formulas, smear tests, or chest X-rays.

In patients with TDL, pulmonary hypertension is associated with the severity of lung destruction\textsuperscript{24}. In the present study, high RV systolic pressure and/or cor pulmonale were present in more than 50% of TDL patients who underwent echocardiography, although no contribution to ICU mortality was observed. Meanwhile, non-survivors had a numerically higher BNP. A BNP of ≥330 pg/mL tended to be associated with mortality and was included in the modified TDL-Vent score. These findings are consistent with the results of previous studies\textsuperscript{2,23,26}, which demonstrated that BNP levels were a prognostic factor in patients with idiopathic pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and chronic cor pulmonale. Although BNP values were available for only 96 of the 125 TDL patients, the present results suggest that further studies are warranted to confirm the utility of BNP in terms of predicting mortality in these patients.

Previous reports show that TDL can cause chronic airflow obstruction\textsuperscript{24,27}. Proposed mechanisms include a reduction in lung volume, a residual limitation of expiratory flow, and a decrease in ventilatory muscle strength and exercise tolerance secondary to poor nutritional status\textsuperscript{17,28,29}. The present results, in which the median FVC, FE\textsubscript{V\textsubscript{1}}, and FE\textsubscript{V\textsubscript{1}}/FVC ratio of the cohort were 48% of predicted, 40% of predicted, and 0.63, respectively, are consistent with those of previous studies. However, as did most previous reports, baseline lung function was not associated with ICU mortality.

The present study had several limitations. First, the study was retrospective and conducted at a single center. Although the study enrolled more mechanically ventilated TDL cases than previous studies, the sample size was relatively small and likely to have been responsible for some of the insignificant results. Moreover, the relatively long study period (>10 years) may have introduced selection and information bias. Second, in attempting to identify risk factors for mortality, high specificity was obtained at the expense of lower sensitivity, as a substantial proportion of patients who died did not have a high TDL-Vent score. Third, a substantial number of patients were excluded from the echocardiography and pulmonary function analyses due to missing data. The inclusion of these patients might have influenced the study results. Lastly, the present study provided a development set only, and the results therefore require independent validation.

In conclusion, the TDL-Vent score is a simple model that may facilitate the prediction of mortality in TDL patients on mechanical ventilation. Prospective validation of the TDL-Vent score in a larger cohort is warranted.

Authors’ Contributions

Conceptualization: Kim WY, Lee K. Methodology: Jo EJ, Eom JS, Mok J, Kim KU, Park HK, Lee MK. Formal analysis: Kim WY. Data curation: Kim WY, Kim MH. Writing – original draft preparation: Kim WY, Kim MH. Writing – review and editing: Jo EJ, Eom JS, Mok J, Kim KU, Park HK, Lee MK, Lee K. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by a 2017 clinical research grant from Pusan National University Hospital. The funders had no role in study design, data collection and analysis, preparation
of the manuscript, or decision to publish.

Supplementary Material

Supplementary material can be found in the journal homepage (http://www.e-trd.org).

Supplementary Figure S1. Locally weighted scatterplot smoothing curves.

References

1. Bobrowitz ID, Rodescu D, Marcus H, Abeles H. The destroyed tuberculous lung. Scand J Respir Dis 1974;55:82-8.
2. Park JH, Na JO, Kim EK, Lim CM, Shim TS, Lee SD, et al. The prognosis of respiratory failure in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis 2001;5:963-7.
3. Ryu YJ, Koh WJ, Kang EH, Suh GY, Chung MP, Kim H, et al. Prognostic factors in pulmonary tuberculosis requiring mechanical ventilation for acute respiratory failure. Respirology 2007;12:406-11.
4. Ryu YJ, Lee JH, Chun EM, Chang JH, Shim SS. Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis 2011;15:246-50.
5. Chakhaia T, Magee MJ, Kempker RR, Gegia M, Goginashvili L, Nanava U, et al. High utility of contact investigation for latent and active tuberculosis case detection among the contacts: a retrospective cohort study in Tbilisi, Georgia, 2010-2011. PLoS One 2014;9:e111773.
6. Calligaro GL, Theron G, Khalfey H, Peter J, Meldau R, Matinyena B, et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial. Lancet Respir Med 2015;3:621-30.
7. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
8. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
9. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A, et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003;228:401-6.
10. Muller NL, Ooi GC, Khong PL, Nicolaou S. Severe acute respiratory syndrome: radiographic and CT findings. AJR Am J Roentgenol 2003;181:3-8.
11. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis 2005;58:230-42.
12. Weitzenblum E. Chronic cor pulmonale. Heart 2003;89:225-30.
13. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003;167:735-40.
14. Cleveland WS, Grosse E, Shyu WM. Local regression models. In: Chambers JM, Hastie TJ, editors. Statistical models in S. Pacific Grove: Wadsworth & Brooks/Cole; 1992. p. 309-76.
15. Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-5.
16. Bishop JM, Cross KW. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Physiopathol Respir 1984;20:495-500.
17. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med 2003;97:1237-42.
18. Chauouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-85.
19. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72.
20. Lee PL, Jerng JS, Chang YL, Chen CR, Hsueh PR, Yu CJ, et al. Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J 2003;22:141-7.
21. Erbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-Ioanas M, Lode H. Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J 2006;27:1223-8.
22. Kim S, Kim H, Kim WJ, Lee SJ, Hong Y, Lee HY, et al. Mortality and predictors in pulmonary tuberculosis with respiratory failure requiring mechanical ventilation. Int J Tuberc Lung Dis 2016;20:524-9.
23. Zahrar JR, Azoulay E, Klement E, De Lasenose A, Luce JC, Regnier B, et al. Delayed treatment contributes to mortality in ICU patients with severe active pulmonary tuberculosis and acute respiratory failure. Intensive Care Med 2001;27:513-20.
24. Jo YS, Park JH, Lee JK, Heo EY, Chung HS, Kim DK. Risk factors for pulmonary arterial hypertension in patients with tuberculosis-destroyed lungs and their clinical characteristics compared with patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017;12:2433-43.
25. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009;103:180-6.
26. Park SY, Lee CY, Kim C, Jang SH, Park YB, Park S, et al. One-
year prognosis and the role of brain natriuretic peptide levels in patients with chronic cor pulmonale. J Korean Med Sci 2015;30:442-9.

27. Rhee CK, Yoo KH, Lee JH, Park MJ, Kim WJ, Park YB, et al. Clinical characteristics of patients with tuberculosis-destroyed lung. Int J Tuberc Lung Dis 2013;17:67-75.

28. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000;55:32-8.

29. Pasipanodya JG, Miller TL, Vecino M, Mungua G, Garmon R, Bae S, et al. Pulmonary impairment after tuberculosis. Chest 2007;131:1817-24.
Supplementary Figure S1. Locally weighted scatterplot smoothing curves. ICU: intensive care unit; PaO$_2$: arterial partial pressure of oxygen; FiO$_2$: fraction of inspired oxygen; PaCO$_2$: arterial partial pressure of carbon dioxide; BNP: brain natriuretic peptide.